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Abstract
Background: Cell-based therapy is a treatment method in tendon injuries. Bone morphogenic protein 12 (BMP-12)
possesses tenogenic activity and was proposed as a differentiating factor for stem cells directed to transplantation.
However, BMPs belong to pleiotropic TGF-β superfamily and have diverse effect on cells. Therefore, the aim of this
study was to determine if BMP-12 induces tenogenic differentiation of human adipose stem cells (hASCs) and how
it affects other features of this population.
Results: Human ASCs from 6 healthy donors were treated or not with BMP-12 (50 or 100 ng/ml, 7 days) and tested
for gene expression (COLL1, SCX, MKH, DCN, TNC, RUNX2), protein expression (COLL1, COLL3, MKH), proliferation,
migration, secretory activity, immunomodulatory properties and susceptibility to oxidative stress. RT-PCR revealed
up-regulation of SCX, MKH and RUNX2 genes in BMP-12 treated cells (2.05, 2.65 and 1.87 fold in comparison to
control, respectively, p < 0.05) and Western Blot revealed significant increase of COLL1 and MHK expression after
BMP-12 treatment. Addition of BMP-12 significantly enhanced secretion of VEGF, IL-6, MMP-1 and MPP-8 by hASCs
while had no effect on TGF-β, IL-10, EGF and MMP-13. Moreover, BMP-12 presence in medium attenuated inhibitory
effect of hASCs on allo-activated lymphocytes proliferation. At the same time BMP-12 displayed no influence on
hASCs proliferation, migration and susceptibility to oxidative stress.
Conclusion: BMP-12 activates tenogenic pathway in hASCs but also affects secretory activity and impairs
immunomodulatory potential of this population that can influence the clinical outcome after cell transplantation.
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Background
Tendon injuries are common musculoskeletal disorders
that clinicians address daily, however, the question of
optimal treatment is still unanswered. Naturally occur-
ring tendon healing is far from satisfactory, because
tendons after injury rarely return to their full mechan-
ical strength [1]. Therefore, trials to improve tendon re-
covery by local supplementation of different bioactive
components are undertaken [2]. One of the proposed
approaches is to implement cellular therapy into treat-
ment protocols both for acute tendon injuries and for
chronic tendinopathies [3]. Mesenchymal stem cells
(MSCs) are considered as the most promising popula-
tion in those applications because of several reasons: 1)
they can undergo tenogenic differentiation [4], 2) they
are suitable for both autologous and allogeneic trans-
plantation, 3) they possess immunomodulatory proper-
ties [5], 4) they stimulate tissue regeneration via
paracrine effect [6]. Another concept to accelerate ten-
don healing is to use local delivery of growth factors
which have tenogenic activity. At present, the most
often proposed candidate for such a treatment is a
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group of highly conserved bone morphogenic proteins
(BMPs): BMP-12, BMP-13 and BMP-14 (also called
growth and differentiation factor 7 (GDF-7), GDF-6
and GDF-5, respectively) [7]. It was originally reported
that subcutaneous or intramuscular administration of
mentioned BMPs resulted in ectopic formation of
tendon-like structure in contrast to BMP-2 which is
well known osteogenic inductor [8]. Later, it was dem-
onstrated that delivery of BMP-12,-13,-14 (either in
form of a gene or a protein) into experimentally injured
tendon improved healing parameters i.e., tensile
strength [9–11]. Finally, it was shown that these BMPs,
especially BMP-12, are able to activate tenogenic path-
way in rat and human bone marrow (BM) derived
MSCs [4, 12, 13]. Thus, based on previously published
studies, the idea of using BMP-12 (-13, -14) treated
MSCs or co-administration of MSCs and discussed
BMPs seems to be a promising approach for tendon
injuries treatment. Recently, much attention is focused
on adipose derived MSCs, which are also called
adipose-derived stem cells or adipose stem (stromal)
cells (ASCs). They constitute attractive alternative to
BM-MSCs as were demonstrated to share most import-
ant features with bone marrow counterparts. Moreover,
fat harvesting is a less invasive procedure than bone
marrow aspiration. However, recently it was shown in
rat cells, that adipose derived MSCs possess weaker
tenogenic activity than bone marrow derived counter-
parts [4]. Therefore, the primary aim of the present
study was to evaluate if BMP-12 activate tenogenic
pathway in human ASCs. However, the MSCs (ASCs)
differentiation potential is only one of several clinically
beneficial features of these cell populations. BMPs
belong to the TGF-β superfamily and are pleiotropic
molecules involved in regulation of multiply fundamental
cellular functions [14]. Moreover, BMP signals influence
various kinds of stem cells with very diverse outcomes
[15]. Although the tenogenic activity of BMP-12 was pre-
viously studied and demonstrated [4, 16], it is not clear
how this cytokine influence on other MSCs (ASCs) fea-
tures. Therefore, we aimed to extend current knowledge
and the secondary goal of this study was to determine
whether treatment of hASCs with BMP-12 affects other
potentially beneficial cells traits like proliferative and
migrative capacity, secretory activity, immunomodulatory
properties and susceptibility to oxidative stress.
Methods
Human adipose stem cells (hASCs) - isolation and
identification
Adipose tissue was collected from healthy donors by
liposuction. Donors were informed and agreed to par-
ticipate in this study. The procedure was approved by
the Local Bioethics Committee. In order to remove red
blood cells, 400 ml fat tissue was mixed 2:1 vol/vol with
buffered physiological salt solution (Phosphate-buffered
saline- PBS) and shaken every 15 min. Following phases
separation, PBS with red blood cells were discarded.
Purification process was repeated three times. After-
wards, 0.075% collagenase solution from Clostridium
histolyticum (Sigma – Aldrich) in PBS was added to adi-
pose tissue (1:2 vol/vol), shaken and incubated in temp.
37 °C for 1.5 h in order to digest the tissue. The fat and
collagenase mixture were shaken every 15 min. After
obtaining a homogenous suspension, human albumin
(20% concentration) was added (final concentration 2%)
to stop the digestion reaction. Mixture was centrifuged
(400 g) for 10 min at room temperature (RT). The liquid
fat and salt interphases were discarded and the cell pellet
was suspended in PBS. Cell suspension was filtered
through 100 μm nylon filter, washed in PBS and centri-
fuged (300 g) for 10 min, RT. The amount and viability
of the cells were determined and cells were seeded into
plastic flasks at a density of 8 × 104 cells/cm2 for further
cultured in growth medium (GM) composed of
DMEM-LG (Dulbecco’s modified Eagle’s Medium with
low glucose; Sigma-Aldrich) supplemented with fetal
calf serum (FCS; 15%; Invitrogen) and antibiotic–anti-
mycotic solution (Penicillin-streptomycin-amfoterycin;
1.5%; Invitrogen) and incubated under standard cell
culture conditions (37 °C, 5% CO2, 95% humidity).
When primary cultures reached subconfluency, cells
were detached by exposure to trypsin (0.25% trypsin
with 1 mM EDTA; Invitrogen) and replated at a density
of 5.0 × 103 cells/cm2 for subsequent passage. After pas-
sage 3 cells were identified by flow cytometry and mul-
tilineage differentiation capacity and were frozen in
liquid nitrogen. For experiments refrozen hASCs from
6 independent donors at passage 4–7 were used.
In vitro osteogenic differentiation
Osteogenic differentiation was performed at the third
passage. Cells were cultured in hMSC Osteogenic Dif-
ferentiation BulletKit™ Medium (Lonza) for 3 weeks.
The medium was changed every 3 days. Osteogenic
differentiation was characterized by identification of
mineral depositions in extracellular matrix. At 3 weeks,
the plated cells were fixed for 15 min with 4% formal-
dehyde and stained with Alizarin Red (Sigma-Aldrich).
After staining, the wells were rinsed with distilled
water and visualized by standard light microscopy.
In vitro adipogenic differentiation
Adipogenic differentiation was performed at the third
passage. Cells were cultured in hMSC Adipogenic Dif-
ferentiation BulletKit™ Medium (Lonza) for 3 weeks.
Adipogenic differentiation was assessed using Oil Red O
(Sigma-Aldrich) stain as an indicator of intracellular
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lipid accumulation. Prior to staining, plastic-adherent
cells were fixed for 45 min with 10% formaldehyde and
then for 5 min with 60% isopropanol. After fixation and
staining, the wells were rinsed with distilled water and
visualized by standard light microscopy.
In vitro chondrogenic differentiation
To induce chondrogenic differentiation, three-dimensional
pellet culture was performed. In a 15 ml tube, 3 × 105 cells
were pelleted by centrifugation. Unsuspended cell pellets
were cultured for 19 days in chondrogenic medium (Lonza)
composed of basic medium supplemented with dexametha-
sone, ascorbate, ITS + supplement, pyruvate, proline, GA-
1000, L-glutamine and recombinant human transforming
growth factor-β3. For histological analysis, pellets were
immersed in paraffin, sectioned and stained with Masson
trichrome method.
Flow cytometry analysis
The surface antigen profiles of adipose derived MSCs at
the third passage were characterized by flow cytometry.
A total of 2,5 × 106 cells were incubated with the fol-
lowing phycoerythrin (PE)-conjugated anti-mouse anti-
bodies: CD29, CD34, CD45, CD73, CD90 and CD105
(Becton Dickinson) for 30 min, RT in the dark. Nonspecific
PE-conjugated IgG was substituted as an isotype control.
The fluorescence intensity of cells was evaluated using BD
FACScalibur flow cytometer equipped with CellQuest Pro
software (Becton Dickinson).
Study design
Cells were grown in Petri dishes (Ø 3.5, 6 or 10 cm, de-
pending on the experiment). At 80% confluence cells
were exposed to growth medium supplemented with
human recombinant BMP-12 (Sigma-Aldrich, SRP4572)
in the concentrations of 50 ng/ml and/or 100 ng/ml
(depending on the test). Cells from the same donors
cultured at the same time in standard GM without
BMP-12 served as a control. Media were changed every
2 or 3 days. After 7 days cells were harvested by trypsi-
nisation, counted and directed either to RNA/protein
isolation, or to functional tests on microplates (prolifer-
ation, migration, oxidative stress susceptibility, mixed
lymphocyte reaction). If certain test required further
culturing, the medium containing or not BMP-12 was
used respectively. Experiments were always conducted
on cells from each donor separately. The cells from differ-
ent donors were not pooled in this study. This approach
allowed for detection inter-individual variations. Unless it
stated differently, all experiments were performed on cells
from 6 different donors n = 6. The scheme of study design
is presented in Additional file 1.
RNA isolation
For gene expression analysis cells were treated for 7 days
with/without 100 ng/ml of BMP-12. At least 3 × 105 cells
were used for this procedure. Isolation of total RNA was
performed using RNeasy Mini Kit (Qiagen) according to
the manufacturer’s instructions. RNA concentration and
purity was assessed by spectrophotometer at 260 nm
using NanoDrop (ND-1000 Spectrophotometer, Nano-
Drop Technologies, Inc).
Real-time PCR analysis
Real-Time PCR was performed on ABI Prism 7500 Se-
quence Detection System using TaqMan® RNA-to-CT™
1-Step Kit (Applied Biosystems, Foster City, USA).
Specific primer and probe set was purchased from Ap-
plied Biosystems: Collagen, type I, alpha 1 (Col1α1)
Hs00164004_m1, Scleraxis (SCX) Hs03054634_g1,
Mohawk homeobox (MKX) Hs00543190_m1, Tenascin
(TNC) Hs01115665_m1, Decorin (DCN) Hs00370385_m1,
Runt-related transcription factor 2 (RunX) Hs01047973_m1,.
GAPDH (4333764 T) gene was used for normalization.
Duplicates of each sample were performed. The relative
expression of mRNA expression was calculated by 2−ΔΔCt
method. The result was presented as a fold change of gene
expression in relation to the calibrator. Statistical analysis
was performed by comparison of dCt values using non-
parametric test for related data (control versus treated
cells from the same population).
Immunocytochemistry (ICC)
To assess the effect of BMP-12 treatment on expression
of collagen type I and type III ICC staining was per-
formed. For this analysis cells were seeded on Nunc™
Lab-Tek™ II CC2™ 8-Chamber Slide System. First, cells
were cultured for 7 day with or without 50 or 100 ng/ml
BMP-12. For ICC quantification, the incubation time of
was shortened to 5 days in order to avoid full confluence
which would hinder subsequent analysis). At the end of
experiment, hASCs were fixed with 4% paraformalde-
hyde (10 min, RT), permeabilized with 70% methanol
(15 min, -20 °C), treated with blocking solution com-
posed of 5% normal donkey serum, 1% of bovine serum
albumin in PBS and probed overnight in 4 °C with
Rabbit polyclonal Anti-Collagen I antibody (Abcam,
ab34710, 1:300) or Rabbit polyclonal Anti-Collagen III
antibody (Abcam, ab7778, 1:150) followed by secondary
Alexa Fluor 594- conjugated Donkey Anti- Rabbit anti-
body (1:150, Jackson ImmunoResearch, 1 h, rt). The
nuclei were visualized with DAPI staining (20 ng/mL of
DAPI solution for 4 min, RT). The result was evaluated
with fluorescence microscopy (Olympus IX51 and Cell-
Sens™ Microscope Imaging Software). The expression of
collagens (type I and III) was measured as the area of
specific fluorescence per cell [μm2]. At least 900 cells
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per well were analyzed from 10 randomly selected fields
of view. Immunocytochemistry was performed on
hASCs from two different donors.
Western blot (WB)
Human ASCs were cultivated with or without BMP-12
(100 ng/ml) for 7 days on Ø 100 mm. culture dishes.
Collected cell pellets were lysed with RIPA buffer
(50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1%
NP-40, 0.25% Na-deoxycholate, and 1 mM PMSF) sup-
plemented with protease inhibitor cocktail and phos-
phatase inhibitor cocktail (Sigma-Aldrich) for 30 min at
4∘C in order to isolate protein extracts. Lysates were
cleared for 20 min at 14000 rpm, and supernatants were
collected. The total protein concentration was deter-
mined using Bio-Rad protein assay dye reagent accord-
ing to the producer’s instructions (Bio-Rad Laboratories
Inc., Hercules, CA, USA). Proteins (35 μg of total pro-
tein per well) were resolved by SDS-PAGE and trans-
ferred onto PVDF membrane (Sigma-Aldrich). For
immunostaining membranes were blocked with 5% non-
fat dry milk in TBS (20 mM Tris-HCl, 500 mM NaCl)
containing 0.5% Tween20. The membranes were incu-
bated with Rabbit polyclonal Anti-Collagen I antibody
(Abcam, ab34710, 1:500) or Rabbit polyclonal Anti-
Collagen III antibody (Abcam, ab7778, 1:1000) or Rabbit
polyclonal Anti-Mohawk antibody (LSBio, aa46-75,
1:1000) or Goat polyclonal Anti-Actin (Santa Cruz
Biotechnology, C-11, sc1615, 1:1000) primary antibodies.
Next the blots were washed three times for 15 min and
incubated with appropriate secondary antibodies conju-
gated with IR fluorophores: IRDye 680 or IRDye 800
CW (purchased from LICOR Biosciences; Lincoln, NE,
USA) at 1:5000 dilution. Odyssey Infrared Imaging
System (LI-COR Biosciences) was used to analyze the
protein expression. Scan resolution of the instrument
was set at 169 μm and the intensity at 5. Quantification
of the integrated optical density (IOD) was performed
with the analysis software provided with the Odyssey
scanner (LI-COR Biosciences). Immunoblot analysis for
cells from each donor was performed on samples from
three independent electrophoreses. For the purpose of
publication the color immunoblot images were con-
verted into black and white images in the Odyssey
software.
Mixed lymphocyte reaction (MLR)
Ten milliliters of venous blood was collected in heparin-
ized tubes from healthy blood donors after obtaining
informed consent. Separation of peripheral blood mono-
nuclear cells (PBMCs) was performed within 2 h of
withdrawal of blood. Blood samples were taken into
preservative-free heparin (20 units/ml) tubes, and
PBMCs were isolated by centrifugation on Histopaque-
1077 (Sigma-Aldrich) of the blood diluted 1:1 with
Sodium Chloride 0.9% (0.9% NaCl, Fresenius Kabi).
PBMCs were taken up in Parker medium (Biomed) sup-
plemented with 2 mM L-glutamine (Sigma-Aldrich),
0.1 mg/ml gentamycin (KRKA), β-mercaptoethanol
(Sigma), 0.23% Hepes (Sigma) and 10% fetal bovine
serum (FBS, Gibco). Half of the isolated PBMCs were
inactivated by gamma-irradiation for 90 min.
hASCs after 7 days culture with BMP-12 were col-
lected and seeded onto 96-well flat-bottom plate
(Greiner) in a concentration of 0.8 × 104/well. Each
time, cells from the same donor cultured in parallel
without BMP-12 were seeded on the same plate in the
identical scheme. Cells were left overnight to attach.
For the MLR, 2 × 105 PBMCs (1 × 105 cells/well from a
first donor and 1 × 105 cells/well from the second
donor) were co-seeded with hASCs in the following
combinations: XXir, YYir, XYir, YXir (X – first donor’s
PBMCs, Xir – irradiated first donor’s PBMCs, Y – sec-
ond donor’s PBMCs, Yir – irradiated second donor’s
PBMCs). PBMC cultures without hASCs were used as
controls. Cells were cultured for 5 days at 37 °C in a
humidified atmosphere with 5% CO2. After 5 days
cells were pulsed with 1 μCi/well of 3H-thymidine
(113 Ci/nmol, NEN) for the last 18 h of the incubation
and harvested with an automated cell harvester (Skatron).
The amount of 3H-thymidine incorporated into the cells
was measured using a Wallac Microbeta scintillation
counter (Wallac), giving the level of radioactivity as ‘Cor-
rected Counts per Minute’ (CCPM). For this experiments
hASCs from 5 different donors were used (n = 5), but the
influence of hASCs from each donor was tested on
PBMCs from two different blood donors (X and Y).
Therefore, 10 separate experiments were performed, each
in triplicate.
Cell proliferation assay
Cell proliferation assay was conducted using a colori-
metric BrdU proliferation ELISA immunoassay (Roche).
hASCs after 7 days culture with or without BMP-12 (50
or 100 ng/ml) were collected and seeded onto 96-well
flat-bottom plate in a concentration of 0.8 × 104/well in
experimental or control medium respectively. The cells
were allowed to grow at 37 °C and 5% CO2 for the next
36 h. Afterwards, BrdU labeling reagent was added to
each well. Then, the cells were further incubated for
12 h, and the pyrimidine analogue BrdU was incorpo-
rated in place of thymidine into the DNA in proliferat-
ing cells. Next, the immunostaining was performed
according to manufacturer instructions. The absorb-
ance was measured at wavelength 450 nm (BioTek
PowerWave XS). Experiments were performed in tripli-
cates for each sample.
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Cell migration assay
The migration assay was performed using trans-well in-
serts with 8 μm pore membrane (BD Biosciences, San
Jose, CA, USA). The wells of the 24-well glass- bottom
plates (SensoPlate, Grainer) was filled with 1 ml of dif-
ferent culture medium: standard GM, GM containing
50 ng/mL BMP-12, or GM containing 100 ng/mL BMP-
12. Human ASCs after 7 days culture with or without
BMP-12 were seeded to the upper compartment of the
cell culture inserts at a density 1.5 × 104 cells per insert
and then inserts were placed into the proper wells. To
allow cell migration from the inserts to the wells, plates
were incubated at 37 °C and 5% CO2 for the next 72 h.
Afterwards, medium was removed and the inserts were
peeled off the cells that migrated to the bottom side of
the membrane using 0.25% tripsin- EDTA solution
(Sigma). After 24 h, when the cells adhere to the bottom
of the wells, hASCs were fixed with 70% methanol and
the nuclei were visualized with DAPI staining (20 ng/mL
of DAPI solution for 4 min). Results were assessed with
a cell imaging multi-mode microplate reader Cytation™ 3
(BioTek) which allowed to specify the number of objects
giving a signal of blue fluorescence (DAPI, wavelength:
377–477 nm). Experiments were performed in duplicates
for each sample.
hASCs viability under oxidative stress in vitro
hASCs after 7 days culture with or without BMP-12
(100 ng/ml) were collected and seeded onto 96-well flat-
bottom plate in a concentration of 0.8 × 104/well in
respective experimental or control medium. Cells were
left to attach and after 24 h were exposed to oxidative
stress by adding a medium with hydrogen peroxide in
increasing concentrations (0, 750, 1000, 1500 μM). After
22 h of incubation, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich)
at the concentration of 5 mg/ml in PBS were added and
incubated for another 2 h. The medium was discarded
and 100 μl of DMSO was added. The plate was shaken
for 10 min using microplate shaker. Absorbance, corre-
sponding to the mitochondrial dehydrogenases activity
of viable cells was measured colorimetrically at wave-
length 570 nm (BioTek PowerWave XS).
Secretory activity
Like in other experiments, hASC were cultured with or
without BMP-12 (100 ng/ml) for 7 days. For the last
48 h the serum was withdrawn from the medium and
cells were incubated with DMEM-LG supplemented
with 4% bovine serum albumin and antibiotics (1%) with
or without BMP-12 respectively. At the end of incuba-
tion period, the supernatants were collected and frozen
in -80 °C. Luminex multiplex assays (Procarta) were
used for measuring concentration of the following
molecules: IL-6, TNF-α, IL-10, EGF, VEGF, MMP-1,
MMP-8 and MMP-13. TGF-β1 concentration was evalu-
ated with ELISA kit (R&D) according to the manufac-
turer’s instruction. All experiments were done in
duplicates.
Statistical analysis
For data analysis STATISTICA software (StatSoft®-
Polska) was used. Data are presented as medians, quar-
tiles and min-max or means ± SEM. Differences between
groups were analyzed by non-parametric Wilcoxon test
for related data or U Mann-Whitney if non-related data
were compared. Student T-test was used if in compared
groups consisted of at least 10 values with normal distri-
bution confirmed by Shapiro-Wilk test. The p value less
than 0.05 was considered as statistically significant.
Results
Cells were successfully isolated from 6 donors. All popu-
lations were able to form colonies and adhere to plastic
surface. To characterize hASCs populations the surface
antigen profiles were examined. Flow cytometry analysis
demonstrated the expression of CD29 (median 93% of
positive cells), CD73 (median 96%), CD90 (median 96%)
and CD105 (median 87%) and revealed no (median less
than 1%) expression of hematopoietic cell lines marker-
CD45. Human ASCs showed the ability to differentiate
into adipocytes, osteocytes and chondrocytes which was
confirmed by specific staining. The representative effect
of differentiation procedure are presented in Fig. 1.
The effect of BMP-12 on tenogenic differentiation of
hASCs
Treatment of hASCs with BMP-12 for 7 days resulted in
an increase of SCLERAXIS and MOHAWK genes expres-
sion (p < 0.05 for both transcription factors). The mean
change in relative expression amounted respectively 2.05
and 2.65 folds in comparison to control, untreated sam-
ples. BMP-12 treatment induced also up-regulation of
osteogenic factor- RUNX2 (mean change in relative ex-
pression was 1.87 fold, p < 0.05). Although the changes
of dCt values for all analyzed transcription factors were
statistically significant, it is worth to stress that the re-
sponse of cells from independent donors was diverse
what illustrates Fig. 2. The gene expression of COLL1α1,
TNC and DCN did not differ significantly. Immunocyto-
chemical method revealed that untreated hASCs
expressed both collagen type I and type III in both tested
populations (Fig. 3a, b). Quantification of ICC results
demonstrated no significant differences between groups
(CTRL vs BMP-12 treated cells, Fig. 3c). To verify those
results, Western blot analysis was additionally performed
and this technique indicated that BMP-12 treatment
(100 ng/ml, 7 days) increased expression of collagen type
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I and mohawk in hASCs (mean 1.8 and 1.5 folds, re-
spectively, both p < 0.05). The expression of collagen
type III was also increased by mean 1.4 fold, but this
change was not statistically significant (Fig. 3d).
BMP-12 do not affect proliferation rate and migration
capacity of hASCs
There were no significant differences between prolifera-
tive rate of hASCs treated with BMP-12 in comparison
to the non-treated cells regardless of the applied BMP-
12 dose (Fig. 4a). Likewise, migration capacity of BMP-
12-treated cells was not significantly different from those
of internal control (Fig. 4b). Those results were consist-
ent among all tested populations (n = 6). Combined re-
sults from all donors are presented in Fig. 4.
BMP-12 significantly increases secretion of VEGF, MMP1,
MMP8 and IL6 in hASCs
BMP-12 (100 ng/ml) treatment (7 days) affected signifi-
cantly hASCs secretory activity in regard to IL-6, VEGF,
MMP-1 and MMP-8. All concentrations were analyzed
using non-parametric Wilcoxon test for related values -
treated sample in comparison to the control sample (un-
treated cells from the same donor). The mean increase
of IL-6 concentration in supernatants after BMP-12
treatment amounted 37% (p = 0.027). The mean increase
of pro-angiogenic VEGF after BMP-12 treatment was
17% (p = 0.046), whereas the mean increase of MMP-1
and MMP-8 concentrations were 41% (p = 0.027) and
21% (p = 0.027) respectively (Fig. 5). In case of IL-6 and
MMP-8 an increase in secretion after BMP-12 treat-
ment was detected in all analyzed populations (n = 6),
whereas in case of VEGF and MMP-1 an increase in
secretion after BMP-12 treatment was noted in 5/6
tested populations. As both proliferation rate (BrdU
assay) and metabolic activity (MTT assay) was no
affected by BMP-12 treatment in the same cells, we
conclude that noted differences were the effect of
BMP-12 action on analyzed hASCs. No significant
changes in secretion of EGF, IL-10, TGF-b I MMP-13
were observed. Combined results from all donors are
presented in Fig. 5.
Fig. 1 Human ASCs differentiation potential. light microscopy: a morphology of undifferentiated hASCs, b hASCs after chondrogenic differentiation,
chondropellet stained with Masson’s Trichrome method, collagen deposits are blue; c, d Alizarin Red staining (calcium deposits are red) of hASCs
cultured in standard (c) or osteogenic medium (d); Oil Red O staining (lipid droplets are red) of hASCs cultured in standard (e) and adipogenic
(f) medium. Representative data from one donor are presented. Scale bars: 50 μm (a, b, c, d); 20 μm (e, f)
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BMP-12 significantly reduces the ability of hASCs to
suppress lymphocyte proliferation
ASCs are known for their immunomodulatory proper-
ties. Mixed lymphocyte reactions (MLR) were performed
to determine whether treatment of hASCs with BMP-12
changes theirs in vitro immunosuppressive activity
(Fig. 6). As expected, the addition of allogeneic irradi-
ated PBMCs from donor Y to PBMCs from donor X re-
sulted in a massive increase in lymphocytes proliferation
(p < 0.01 in comparison to auto-stimulated cells). The
addition of hASCs to the mixture of PBMCs (X + Yir or
opposite) significantly inhibited allo-activated lympho-
cytes proliferation (p = 0.016) to the level which was not
significantly different than in control lymphocytes
(auto-stimulated). This inhibition was significantly de-
creased when hASCs were previously exposed to
50 ng/ml BMP-12 for 7 days (p = 0.037 between X +
Yir + hASCs and X + Yir + hASCs + BMP-12 (50), a de-
crease observed in 8/10 observations). Similar effect (a
decrease in inhibition in 8/10 observations) was noted
in reaction with cells treated with 100 ng/ml BMP-12,
but the difference between X + Yir + hASCs and X + Yir
+ hASCs + BMP-12(100) did not reach statistical sig-
nificance. In reactions, where hASCs were treated with
BMP-12 (both 50 and 100 ng/ml) lymphocyte prolifer-
ation became significantly higher than in control auto-
stimulated ones. Figure 6 presents combined data from
5 hASCs donors (each paired with 2 different PBMCs
donors, giving together 10 observations).
BMP-12 do not change the susceptibility of hASCs to
oxidative stress
The effect of oxidative stress on cells viability was deter-
mined in MTT test. In both control and BMP-12 treated
cells there were significant differences in viability after
24 h exposure to growing concentrations of hydrogen
peroxide compared to H2O2 untreated sample. Differ-
ences were analyzed sing non-parametric Wilcoxon test.
BMP-12 treatment had no effect on hASCs resistance
to oxidative stress - in both, control and BMP-12
exposed cells, 750 μM of H2O2 was required to signifi-
cantly (p < 0.05) impair cell viability (Fig. 7). Addition-
ally, the comparison of BMP-12 untreated and treated
hASCs viability was performed within certain level of
oxidative stress (750, 1000, 1500 μM). The analysis was
performed using U Mann Whitney test. No significant
differences were detected, the results were consistent
among tested populations (n = 6) and in combined ver-
sion are presented in Fig. 7.
Discussion
Mesenchymal stem cells are considered as a candidate
population for cell therapy in many different applications
including orthopedic disorders like non-union bone frac-
tures, osteoarthritis or more recently, tendon injuries
[17]. In orthopedics, cell administration is usually local
(not systemic) and it is excepted that cellular transplant-
ation will improve regeneration of target tissue. Never-
theless, there are at least three different mechanisms by
which MSCs potentially ameliorate tissue healing: 1) via
differentiating, 2) via paracrine activation of endogenous
progenitor cells and promoting angiogenesis, 3) via con-
trolling inflammatory response and directing macro-
phages into M2 phenotype. The first, most obvious and
primarily described mechanism is acting through differ-
entiating into the target tissue cells. The capacity of
MSCs (regardless of their source) to enter osteogenic
and chondrogenic pathway is undoubtful and became
one of identification requirement [18]. The ability to dif-
ferentiate into tenocytes is not so well documented and
not so easy to proof. Presented herein results demon-
strate that BMP-12 induced up-regulation of genes for
main transcription factors associated with tenogenesis.
Previously, BMP-12 was shown to activate tenogenic
pathway in rat and human bone marrow derived MSCs
[12, 13]. In regard to adipose derived stem cells, the ef-
fect of BMP-12 treatment was studied on canine [16]
and human cells [19]. It is important to stress that it is
difficult to clearly state if a cell (especially in 2D culture)
is already a tenocyte or not. There is no unequivocal
method to recognize completed tenogenic differentiation
as it is a case in osteogenesis (extracellular calcium
deposits formation) or adipogenesis (intracellular lipid
droplets). Tenocytes produce large amount of ECM
Fig. 2 BMP-12 treatment activates tenogenic pathway in hASCs. Real
time PCR in human adipose stem cells (hASCs) treated or not with
100 ng/ml BMP-12 for 7 days. Results presented as fold of change in
relation to the internal control samples (cells from the same donor
cultured in parallel in standard growth medium). hASCs obtained
from 6 independent donors were used. Col1a1- Collagen, type I,
alpha 1; DCN- Decorin; RUNX- Runt-related transcription factor 2;
MKX- Mohawk homeobox; SCX- Scleraxis; TNC- Tenascin; GAPDH
gene was used for normalization
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Fig. 3 The effect of BMP-12 treatment on tendon associated proteins expression in hASCs. a, b Immunocytochemistry (ICC). The expression of
collagen I (a) and collagen III (b) (were stained in red) in hASCs cultured for 7 days in standard medium (control, upper panel), or in medium
supplemented with 100 ng/ml BMP-12 (lower panel). Nuclei were stained with DAPI (blue). All pictures present cells from the same donor and
the same experiment. Scale bars - 20 μm. c Quantification of ICC results. The collagen I and III area per cell was calculated [μm2] after 5 days
culture in medium with or without BMP-12 (50 or 100 ng/ml). Data obtained from 2 donors. For each treatment/protein/donor at least 900
cells were subjected to analysis. Kruskal–Wallis one-way analysis of variance detected no statistical differences between groups (ns). d Western
blot analysis for collagen I, collagen III and mohawk. Expression of actin was used as a loading control. Graphs below representative bands
demonstrate densitometric analysis (normalized to IOD of corresponding actin). The results presented as means ± SEM from three donors
(at least three separate electrophoreses per donor performed and analyzed). Data analyzed using non-parametric Wilcoxon test in comparison
to internal control (BMP-12 untreated cells from the same donor and electrophoresis).* - p < 0.05
Fig. 4 BMP-12 treatment does not affect neither hASCs proliferation nor their migration. a Proliferation activity of hASCs determined using a
colorimetric BrdU proliferation ELISA immunoassay after culture in the presence of BMP-12. Cells from the same donor cultured in parallel in
standard growth medium were used as a control. b Trans-well migration test (inserts with pore 8 μm). hASCs migration evaluated after 7 days
culture with or without BMP-12. Data presented as relative values to the internal control (untreated hASCs from the same, respective donor); the
number of donors n = 6, tests performed in triplicates (a) or in duplicates (b). No statistically significant differences were detected
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composed predominantly of collagen type I which is the
most abundant ECM component in the whole organism
and many cell types including undifferentiated MSCs ex-
press this protein. Other ECM molecules associated with
tenocytes are collagen type III, decorin, tenascin C, teno-
modulin, however, none of them is exclusively expressed
by tenocytes. Herein, it was confirmed that undifferenti-
ated hASCs produce both key tendon associated colla-
gens: type I and III (Fig. 3a,b). The effect of BMP-12 on
protein expression of collagen type I and III was ana-
lyzed in this study with two methods - quantified ICC
and WB. In regard to collagen type I expression the
results were not consistent - ICC revealed lack of
significant difference between control and treated cells
whereas WB demonstrated statistically significant in-
crease of collagen type I after BMP-12 treatment
(Fig. 3d). As all cells expressed collagen type I, the ICC
analysis could reflect rather cell size than the actual pro-
tein expression. Therefore, WB in this case seems to be
a superior method. Other factors identified as key teno-
genic markers are transcription factors: scleraxis and
mohawk [12, 20], nonetheless those proteins are also
expressed by undifferentiated MSCs [16]. Therefore, an
in vitro evaluation of tenogenesis in two dimensional
culture is always based only on relative changes in set of
molecules expression. In our study we noticed an
Fig. 5 BMP-12 treatment affects secretory activity of hASCs. Cytokines (a), growth factors (b) and metalloproteinases (c) determined in serum free
supernatants collected from above hASCs treated or not with 100 ng/ml BMP-12 (7 days, supernatants collected from last 48 h). Data presented
as mean +/- SEM. Results analyzed using non-parametric Wilcoxon test in comparison to internal control (BMP-12 untreated cells from the same
donor).* - p < 0.05. All tests were performed in duplicates; n = 6 donors
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increase of tenogenic transcription factors in hASCs
after BMP-12 treatment what is in agreement with previ-
ous studies performed on MSCs from other sources or
species [12, 16, 19]. One previous research on human
ASCs [19] showed increased expression of genes after
BMP-12 treatment, but only an increase in DECORIN
expression was statistically significant. In the mentioned
study tenogenesis inducing medium contained reduced
serum concentration (1% FBS) compared to control
growth medium (10% FBS). For this reason cannot be
unambiguously assess whether the decrease in the serum
concentration can induce tenogenic path without the
addition of BMP-12. In the present study, the differences
in tenogenic transcription factors expression achieved
statistical significance, however, the mean change (2-fold
increase in case of SCLERAXIS) was very similar to re-
sults presented by Stanco et al. [19]. Presented herein
results demonstrate also up-regulation of MOHAWK
after BMP-12 treatment what is in agreement with data
reported by Otabe et al [12]. In our study we further
confirmed increased MOHAWK expression in response
to BMP-12 by Western blot analysis. Nevertheless, in
cells treated with BMP-12 we also noticed up-regulation
of osteogenic transcription factor RUNX2 (p < 0.05). Al-
though it was demonstrated that BMP-12,-13 possess
significantly lower osteogenic activity than classical bone
associated BMP-2 [21], certain level of osteogenic BMP-
12 potential was presented in other studies [16]. Ectopic
tissue calcification is one of the concerns associated with
MSC-based therapy. Moreover, tenogenic and osteogenic
intracellular signaling pathways are very similar. There-
fore, a risk of unfavorable differentiation in case of
BMP-12 treatment should be further investigated.
Another described mechanism by which MSC can im-
prove tissue regeneration is to promote angiogenesis
through secreted molecules. The key mediators of new
blood vessel formation are vascular endothelial growth
factors. Mesenchymal stem cells are known to be a
stable source of VEGF [22]. Presented herein results
show that BMP-12 treatment significantly enhances se-
cretion of VEGF by hASCs. It was previously demon-
strated that VEGF secretion can be a crucial mechanism
of MSCs action in nerve repair [23], wound healing [24],
myocardium regeneration [25] or recovery from acute
kidney injury repair [26]. In regard to tendon associated
disorders, the role of VEGF is not so clear. In chronic
tendinopathies, neovascularisation is perceived as un-
favorable process which leads to painful neoinnervation
[27]. On the other hand, in acute tendon injuries VEGF
is rather a beneficial player. Its secretion was shown to
be important in improvement of tendon graft matur-
ation and biomechanical strength during anterior cruci-
ate ligament healing after stem cell transplantation [28].
Similarly, administration of exogenous VEGF to the
experimentally injured tendon enhanced healing param-
eters in comparison to the control, untreated animals
[29, 30]. Finally, the relatively low level of endogenous
VEGF mRNA following injury, supports its potentially
beneficial role as exogenous modulator to optimize ten-
don healing and strength [31]. The relationship between
BMP-12 (-13, -14) treatment and VEGF secretion has
not been previously demonstrated, however, it was re-
ported that BMP-4 significantly stimulated VEGF syn-
thesis in osteoblast-like MC3T3-E1 cells [32]. The
authors later proofed that this interaction was MAP kin-
ase- dependent [33]. The release of VEGF by MSCs was
Fig. 6 BMP-12 treatment impairs immunomodulatory properties of
hASCs. The effect of hASCs treated or not with BMP-12 (a. 50 ng/ml
and b. 100 ng/ml) for 7 days on proliferation of PBMCs (peripheral
blood mononuclear cells) in Mixed Lymphocytes Reaction (MLR).
PBMCs from two independent donors X and Y were used for each
experiment. Isolated PBMCs were stimulated in autologous or allogeneic
manner (by addition of irradiated PBMCs from the same or second
donor respectively). Mixture was cultured with or without
addition of hASCs (treated with BMP-12 or not). +/- indicates the
presence of a given component. Data presented as means and
SEM. Results analyzed with Student T test or non-parametric
Wilcoxon test depending on distribution. Letters above bars indicate
statistical differences: groups sharing the same letter do not differ
significantly (p < 0.05). Number of hASCs donors n = 5, each hASC
population tested with PBMCs from two different donors (X and Y).
The amount of 3H-thymidine incorporated into the cells giving the
level of radioactivity as ccpm – corrected counts per minute, tests
performed in triplicates
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demonstrated to be mediated by both STAT3 and p38
MAPK [34]. Generally, the basic signaling process for
bone morphogenic proteins goes through Smads activa-
tion (Smad 1/5/8) [15]. Activation of this particular
pathway was also confirmed specifically for BMP-12 in
canine ASCs [16]. Nevertheless, it was shown by Naka-
shima et al. that interaction between STAT3 and Smads
can occur resulting in a synergistic signaling effect [35].
This phenomenon could be one of possible explanations
BMP- VEGF secretion interrelation.
Interestingly, another molecule which was herein
shown to be affected by BMP-12 treatment is IL-6. This
cytokine was initially described as a classical pro-
inflammatory molecule because its serum concentration
was found to be significantly elevated in patients with
various inflammatory diseases [36]. Later, it was shown,
that IL-6 is a pleiotropic cytokine which can exert both
pro- and anti-inflammatory effect [37]. It is believed that
the way of action depends on the signaling pathway:
either it is classic signaling thought membrane bound
IL-6R (anti-inflammatory effect) or trans-signaling
thought soluble IL-6R which interact with gp130 protein
(pro-inflammatory effect) [38]. Mesenchymal stem cells
are known to be an abundant source of IL-6 [39] which
was confirmed in the presented study. We additionally
shown that BMP-12 treatment elevates the secretion rate
of this cytokine by hASCs. Because of mentioned dual
role of IL-6 in inflammatory reaction it is difficult to
predict what consequences would have an increased
level of IL-6 in in vivo situation after cell transfer - prob-
ably the effect will depend on local inflammatory status
of a host tissue. As interleukin-6 acts intracellularly
through STAT-3, it might be that elevated extracellular
level of IL-6 induces STAT-3 dependent pathway in
ASCs and by previously mentioned interaction with
Smads can enhance VEGF secretion. It is also possible
that increased level of IL-6 is related to the decreased in-
hibition of PBMCs proliferation by ACSs after BMP-12
treatment. It is known that IL-6 in combination with
TGF-β triggers differentiation of naive Th cells towards
Th17 pathway and inhibits the generation of Foxp3+ T
regulatory cells induced by TGF-beta [40]. On the other
hand, one of MSCs immunomodulatory mechanisms is
to cause an increase in the proportion of regulatory T
cells in PBMCs [41]. The TGF-β level secreted by ASCs
persists unchanged and the IL-6 release is elevated
under BMP-12 exposure. Therefore it is possible that
more naive T cells in co-culture with BMP-12 treated
ASCs differentiate toward Th17 than into T reg cells in
comparison to the co-culture with untreated ASCs. This
hypothesis remains to be verified. However, regardless of
the mechanism, our results suggest that BMP-12 pre-
treatment or co-administration can be contraindicated
in allogeneic ASCs (MSCs) therapies.
The key molecular feature of tendon tissue is the com-
position of extracellular matrix and its specific spatial ar-
rangement. Therefore, effective remodeling of tendon
ECM after injuries is particularly important. The crucial
players in this process are matrix metalloproteinases, in-
cluding those responsible for degradation of type I colla-
gen which are MMP-1, MMP-8 and MMP-13
investigated in this study. All of them are released by
mesenchymal stem cells irrespective of their source [42]
and we demonstrated herein that BMP-12 treatment sig-
nificantly elevated the secretion of MMP-1 and MMP-8
by human adipose derived stem cells. MMPs were
shown to have role in physiological tendon healing [43],
but on the other hand it is suggested they are involved
in pathogenesis of chronic tendinopathies i.e., rotator
cuff disease [44]. Tendon tissue is constantly turned over
with higher rates at sites exposed to high level strain. It
is believed the lost of balance between MMPs and their
Fig. 7 BMP-12 treatment does not affect susceptibility of hASCs to oxidative stress in vitro. MTT test. Metabolic activity (related to viability) of
hASCs after exposure to growing concentrations of hydrogen peroxide (24 h exposure). a control hASCs (cells from the same donor cultured
without BMP-12); b hASCs after BMP-12 treatment (100 ng/ml, 7 days before exposure to H2O2). Data presented as medians, quartiles and
min-max. Results analyzed using non-parametric Wilcoxon test in comparison to H2O2 untreated sample.* - p < 0.05. All tests were performed
in triplicates; number of hASCs donors n = 6
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inhibitors can predispose to a chronic tendinopathies.
Among collagenases, MMP-1 and MMP-13 were shown
to be up-regulated in rotator cuff tear [45, 46]. There-
fore, our results showing increased release of MMP-1 by
hASCs after BMP-12 treatment suggest that using this
protein in combination with cell therapy can be not
beneficial in chronic tendinopathies.
Potential use of BMP-12 in combination with MSCs
(ASCs) therapy required examination of BMP-12 effect
on basic cellular activities like proliferation and migra-
tion. BMPs belongs to TGF-β superfamily which gener-
ally are known to inhibit cell proliferation [47]. However,
it can be concluded from different studies that effect of
BMPs on cell proliferation vary between both cell types
and different BMPs. For example, BMP-3 were shown to
promotes MSCs proliferation [48] whereas BMP-9 inhib-
ited bFGF induced proliferation of endothelial cells [49].
Our results demonstrated that BMP-12 (50 or 100 ng/
ml) had no influence on hASCs division rate what is in
agreement with data presented by Haddad-Weber et al.
[50]. Also, BMP-14 (GDF-5) was demonstrated to not
affect human MSCs proliferation [51]. This finding is in
accordance with the weak effect of BMP-12 on hASCs
tenogenic differentiation which was observed in this
study. It is generally accepted that the process of differ-
entiation into relatively stable tissues like muscle, bone
or tendon is associated with the significant decrease of
proliferation in progenitor cells. In regard to cell migra-
tion, the effect of BMPs is not well recognized. In the
discussed study, we demonstrated that BMP-12 had no
effect on hASCs migration capacity what seems to be
beneficial in term of potential local cell administration.
Conclusions
In summary, MSC-based therapy is a promising treat-
ment method in many orthopedic conditions including
different tendon disorders. One of proposed approach in
stem cell transplantation is to pre-differentiate cells in
vitro before injection to activate certain pathways and fa-
cilitate direct regeneration of disabled tissue. In the
present study we demonstrated that BMP-12 induces
tenogenic pathway in human hASCs as it up-regulates
key tenogenic transcription factors (SCLERAXIS and
MOHAWK). However, BMP-12 treatment affected not
only differentiation process in hASCs. It caused also sig-
nificant changes in secretory activity of treated cells and
impaired their immunomodulatory properties. The en-
hanced secretion of VEGF and collagenases could pos-
sibly improve regeneration process in acute tendon
injuries, but in chronic tendinopathies, neoangiogenesis
and MMP over-activity are rather markers of pathologic
processes. Therefore, our results suggest that BMP-12
could be a candidate for cell pretreatment in cases of
acute tendon injuries, but not in chronic tendinopathies.
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